Eftansomatropin alfa
Based on 1 Customer Validation
Eftansomatropin alfa (GX-H9) is a fusion protein composed of rhGH (growth hormone) and immunoglobulin fragments. In Eftansomatropin alfa, rhGH is fused to a hybrid Fc domain comprising sequences of both IgD and IgG4. Eftansomatropin alfa can be used for the study of growth hormone deficiency (GHD).
For research use only. We do not sell to patients.
- Purity : 99.00%
- CAS No.: 1905448-17-0
- Molecular Weight:100.072 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Fusion-[GH1]1-IGHG4 Fc
Species Reactivity
Human
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Fusion-[GH1]1-IGHG4 Fc
Chemical Information
-
CAS No. 1905448-17-0
-
Appearance Liquid
-
Molecular Weight 100.072 kDa
-
Color Colorless to light yellow
-
SMILES
[Eftansomatropin alfa]
-
Synonyms
TJ-101; GX-H9; hGH-hyFc; HL-2356
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
-
Data Sheet (254 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Eftansomatropin alfa Related Classifications
HY-P99932 Related Classifications
Powered by Bioz